Date: 2012-09-11
Type of information: Grant
Company: Arsanis Biosciences (Austria)
Investors: Austrian Research Promotion Agency (Austria)
Amount: €1.54 million
Funding type: grant
Planned used: This grant will contribute to progress of Arsanis Biosciences\'antibody discovery efforts towards companion diagnostics and monoclonal antibody based therapeutics against severe infections caused by Staphylococcus aureus and multi-drug resistant Escherichia coli. It will contribute to the timely delivery in the pre-clinical testing of product candidates and to initiate GMP manufacturing.
Others: Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, has been awarded €1.54 million by the Austrian Research Promotion Agency (Österr. Forschungsförderungs GmbH or “FFG”), the leading public funding agency for applied research in Austria. This support is given for the 2nd year of a 4-year “Basisprogramm” project with a total budget of ® 12.5 million (with up to 70% funding).
Therapeutic area: Infectious diseases
